Bart Cornelissen

UHD (associate professor)

University Medical Center Groningen

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Medical Imaging Medical Imaging professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Bart Cornelissen is an Associate Professor at the University Medical Center Groningen in the Netherlands. His research focuses on radiochemistry and radiopharmacy, with recent articles highlighting advancements in targeted radionuclide therapy and the development of innovative radiopharmaceuticals for cancer treatment. He is actively involved in preclinical evaluations and methodologies for enhancing therapeutic efficacy in oncology.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

António Paulo

PORTUGAL

View details

James C. Knight

Newcastle University

UNITED KINGDOM

View details

Janine Doorduin

University Medical Center Groningen

NETHERLANDS

View details

MANUEL SARMIENTO SOTO

Lecturer

Universidad de Sevilla

SPAIN

View details

Sarah Spreckelmeyer

Head of Radiopharmacy

Charité - Universitätsmedizin Berlin

GERMANY

View details

Samantha Terry

King’s College London

UNITED KINGDOM

View details

A. W. J. M. Glaudemans

University Medical Center Groningen

NETHERLANDS

View details

Edward O'Neill

University of Oxford

UNITED KINGDOM

View details

Doreen Lau

Lecturer (Assistant Professor)

Brunel University London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bart Cornelissen

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy

A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment

Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer

Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT

Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics

Multicomponent Reactions: A Promising Approach to Isotope Labeling

In Vivo PET Detection of Lung Micrometastasis in Mice by Targeting Endothelial VCAM-1 Using a Dual-Contrast PET/MRI Probe

[15O]H2O PET

Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy

Second Symposium of the European Working Group on the Radiobiology of Molecular Radionuclide Therapy

Imaging DNA damage response by γH2AX in vivo predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome

[<sup>123</sup>I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer

A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy.

Boronic ester functionalised 1,8-diboryl-naphthalene scaffolds: fluoride <i>versus</i> oxide chelation.

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [<sup>18</sup>F]olaparib in mouse models of glioma.

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Imaging PARP with [18F]rucaparib in pancreatic cancer models

Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent

Collaborators (9)

António Paulo

James C. Knight

Janine Doorduin

MANUEL SARMIENTO SOTO

Sarah Spreckelmeyer

Samantha Terry

A. W. J. M. Glaudemans

Edward O'Neill

Doreen Lau

Make your next move.